International Trade Commission September 16, 2022 – Federal Register Recent Federal Regulation Documents

Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 in the above-captioned investigation. The Commission has determined to issue: (1) a limited exclusion order (``LEO'') prohibiting the unlicensed entry of infringing plant-derived recombinant human serum albumins (``rHSA'') and products containing the same covered by certain claims of U.S. Patent No. 10,618,951 that are manufactured by or on behalf of, or imported by or on behalf of, respondents Wuhan Healthgen Biotechnology Corp. (``Healthgen''); ScienCell Research Laboratories, Inc. (``ScienCell''); Aspira Scientific, Inc. (``Aspira''); and eEnzyme LLC (``eEnzyme'') or any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns; and the entry of plant-derived rHSAs and products containing the same that include a false designation of origin that are manufactured by or on behalf of, or imported by or on behalf of, ScienCell, Aspira, or eEnzyme or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns; and (2) cease and desist orders (``CDOs'') directed against ScienCell, Aspira, and eEnzyme, and any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns. This investigation is terminated.